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Abstract 
 
This study compared effects of five hypoxia-inducible factor (HIF) prolyl hydroxylases 
(PHD) inhibitors on PC12 cells and primary rat neurons following oxygen-glucose 
deprivation (OGD). At 100 µM, the PHD inhibitors did not cause cytotoxicity and apoptosis. 
MTT activity was only significantly reduced by FG4592 or Bayer 85-3934 in PC12 cells. The 
PHD inhibitors at 100 µM significantly increased the LC3-II/LC3-I expression ratio and 
downregulated p62 in PC12 cells, so did FG4592 (30 µM) and DMOG (100 µM) in neurons. 
HIF-1α was stabilised in PC12 cells by all the PHD inhibitors at 100 µM except for DMOG, 
which stabilised HIF-1α at 1 and 2 mM. In primary neurons, HIF-1α was stabilised by 
FG4592 (30 µM) and DMOG (100 µM). Pretreatment with the PHD inhibitors 24 hours 
followed by 24 hour reoxygenation prior to 6 hours OGD (0.3% O2) significantly reduced 
LDH release and increased MTT activity compared to vehicle (1% DMSO) pretreatment. In 
conclusion, the PHD inhibitors stabilise HIF-1α in normoxia, induce autophagy, and protect 
cells from a subsequent OGD insult. The new class of PHD inhibitors (FG4592, FG2216, 
GSK1278863, Bay85-3934) have the higher potency than DMOG. The interplay between 
autophagy, HIF stabilisation and neuroprotection in ischaemic stroke merits further 
investigation. 
(200) 
Keywords: hypoxia inducible factor (HIF), HIF prolyl hydroxylase (PHD) inhibitors, stroke, 
oxygen glucose deprivation (OGD), neuroprotection, autophagy.  
 
 
 
 
 
 
 
 
 
 
 
 
3 
 
 
1. Introduction  
 
The hypoxia inducible transcription factors (HIF) are regulators of cellular responses to 
hypoxia in mammals. HIF mediated responses involve increases in the expression of multiple 
genes in a context dependent manner, including those associated with erythropoiesis and 
angiogenesis (1). Under normoxic conditions, efficient catalysis by the ferrous iron and 2-
oxoglutarate (2OG) dependent HIF prolyl hydroxylases (PHDs 1-3 in humans) promotes  
binding of HIF-α to the VHL (Von Hippel Lindau) tumour suppressor protein which is a 
targeting component of an E3 ligase complex, resulting in proteasomal degradation of HIF-α 
(2). The action of a second 2-oxoglutarate (2OG) dependent HIF hydroxylase, the asparginyl 
hydroxylase, factor inhibiting HIF (FIH), regulates HIF activity by reducing its binding with 
histone acetyl transferases (2). During hypoxia, PHD activity is reduced resulting in the 
stabilization and accumulation of HIF-1α in the cytoplasm, which then translocates to the 
nucleus forming the HIF transcription factors that upregulate expression of multiple genes 
(3). The array of genes targeted by the HIF system makes it an appealing pharmacological 
target, in particular via PHD inhibition mediated HIF upregulation for treatment of diseases 
including anaemia, ischaemic stroke, and wound healing (4). Currently, four PHD inhibitors 
i.e. FG4592 (Roxadustat) from FibroGen, GSK1278863 (Daprodustat) from 
GlaxoSmithKline, Bay85-3934 (Molidustat) from Bayer and AKB-6548 (Vadadustat) from 
Akebia are in clinical use or trials for anaemia treatment in patients with chronic kidney 
disease (CKD) (5,6).  
 
A number of HIF PHD inhibitors (e.g. GSK360A, FG4497, FG2216, DMOG, DFO) have 
been studied in stroke models either in vivo or in vitro, where these compounds showed 
neuroprotective effects following an ischaemic insult (7-12). Nevertheless, the role of HIF in 
stroke pathophysiology remains debatable (13). Neuronal specific HIF-1α knock out mice 
resulted in a worse neurological outcome and larger infarct volume following 30min middle 
cerebral artery occlusion (MCAO) (14); however, the neuronal specific HIF-1α knock out 
mice had better neurological outcomes after 75min global ischaemia (15). Single HIF1α or 
HIF-2α knock out mice had a similar infarct volume following MCAO compared to the 
respective wild type mice, possibly due to a mutual compensation (16). HIF-1α/2α double 
knock out mice were observed to be significantly more impaired 72 hour after the MCAO 
suggesting HIF can be involved in functional recovery after cerebral ischaemia (16).  The 
effects of HIF on the ischaemic brain vary depending on the severity and/or duration of the 
stroke (13).  Whilst indirect induction of HIF, via genetic ablation of PHD1 or PHD2, 
reduced infarct volume and improved sensorimotor function following transient ischaemia 
(17, 18). The pharmacological inhibition of PHD2, and/or PHD1 could stimulate adaptations 
that provide protection against damage from ischaemic stroke (4, 13).  A pharmacological 
approach for ischaemic cerebral tolerance is clinically appealing due to its non-invasive 
application. Currently, no available drug specifically inhibits a single PHD isoform, as such, 
researchers have mostly focused on generating inhibitors targeting PHD2, as it is proposed to 
be the most important PHD isoform in regulating HIF levels in normoxia (5). 
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This study aimed to characterize effects of three clinical HIF-PHD inhibitors (FG4592, 
GSK1278863, Bay85-3934) alongside FG2216 (IOX3) and DMOG (dimethyloxalylglycine), 
a non-specific 2OG analogue, using an in-vitro oxygen-glucose deprivation (OGD) model. 
These chemicals activate the HIF signalling pathway in normoxia, with somewhat different 
effects (19), which we considered could be reflected in specific effects on ischaemic neurons. 
 
2. Results  
 
 
2.1. PC 12 cells 
 
 
2.1.1. Effects of PHD inhibitors on PC12 cell viabilities and apoptosis in normoxia 
 
PHD inhibitors are widely used to mimic hypoxia in vitro, where they are initially dissolved 
and administered with DMSO. However, DMSO is a redox active small molecule and 
therefore could affect cell behaviour. In order to determine effects of DMSO on PC12 cells, a 
range of DMSO concentrations (0.5-10%) were administered to PC12 cells for 24 hours in 
normoxia. Both 5% and 10% DMSO produced significant reduction in MTT activity and 
increase in LDH release. Moreover, 2% DMSO produced a slight but significant reduction in 
MTT activity. The remaining concentrations of DMSO had no significant effects on MTT 
activity or LDH release compared to PC12 cultures into which no DMSO was added (Fig. 
S1). A concentration of 1% DMSO was therefore used in subsequent work to dissolve the 
PHD inhibitors. 
 
We then evaluated the effects of varying concentrations (1, 10, 50, 100 µM) of the PHD 
inhibitors (FG2216, FG4592, GSK1278863 and Bay85-3934) and DMOG (1, 10, 50, 100, 
250, 500 µM, 1 mM and 2 mM) in PC12 cell viabilities for 24 h in normoxia (21% O2), using 
MTT (mitochondrial activity), LDH (cytotoxicity) and trypan blue exclusion (cell viability) 
assays. Under 100 µM, the 4 “clinical” compounds did not manifest evidence for cytotoxicity 
(Fig. 1B), nor cause significant changes in the fraction of live cells (Fig. 1C). On the other 
hand, DMOG (500 µM, 1 mM and 2 mM) caused significant cytotoxicity and reduction in 
fraction of live cells. At high concentrations, two of the “clinical” compounds (FG4592, 100 
µM and Bay 85-3934, 50 & 100 µM) and DMOG (250 µM, 500 µM, 1 mM and 2 mM) 
significantly reduced MTT activity, while the other compounds had no significant apparent 
effects on mitochondrial activity (Fig. 1A). Annexin-V (AV)/7-AAD FACS analysis was 
performed to determine whether the PHD inhibitors resulted in apoptosis. 24 hours oxygen 
deprivation was performed as a positive control (Fig. S2). The results revealed no significant 
changes in viable (AV-/7-AAD-), early apoptotic (AV+/7-AAD-) and late apoptotic/necrotic 
(AV+/7-AAD+) in cells treated with the PHD inhibitors (100 µM) in comparison to 1% 
DMSO (vehicle) (Fig. 2).  
 
2.1.2. Effects of PHD inhibitors on autophagy  
We thereafter studied the effect of 24 hours treatment with the PHD inhibitors (100 µM) on 
LC3b (microtubule associated protein light-chain 3b), p62 (sequestosome-1, SQSTM1) and 
Beclin1 (BCN1) expression. Rapamycin, an established, autophagy inducer, was used as a 
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positive control. There was a significant increase in LC3b-II/LC3b-I ratio and reduction in 
p62 in cells exposed to 1 and 10 µM of Rapamycin (Fig. 3). A significant increase in the 
LC3b-II/LC3b-I ratio was also seen in cells exposed to DMOG, FG2216 and FG4592, but at 
slightly lower levels compared to GSK1278863 and Bay85-3934. In comparison to 1% 
DMSO (vehicle) treated cells, there was significant downregulated in p62 in cells exposed to 
DMOG, FG2216, FG4592, GSK1278863 and Bay85-3934. A significant increase in Beclin1 
was seen in cells exposed to FG4592, GSK1278863 and Bay85-3934 (100 μM) but not in 
cells exposed to Rapamycin (1, 10 μM) and DMOG (100 μM).  
 
2.1.3. Effects of PHD inhibitors on HIF-1α protein expression  
Next, we investigated HIF-1α stabilisation at 24 hours PHD inhibitor treatment in normoxia. 
No significant stabilisation of HIF-1α was seen at concentrations of 1, 10 and 50 µM (data 
not shown). Significantly increased HIF-1α levels were observe in cells exposed to 100 µM 
of all the PHD inhibitors (FG2216, FG4592, GSK1278863 and Bayer 85-3934) (Fig. 4B), 
except for DMOG. Further studies demonstrated that HIF-1α was significantly stabilised in 
cells exposed to 1 mM and 2 mM of DMOG for 24 hours (Fig. 4C).  
 
2.1.4. Hypoxia gene expression affected by the PHD inhibitors 
Using qRT-PCR, we then investigated whether the PHD inhibitors (at 100 µM) have an effect 
on hypoxia gene expressions (Hif1α, Bnip3, Phd2, Vegf, Pfkfb1, Pfkfb3, and Ldha) in PC12 
cells (Fig. 5). Of all the genes studied, Pfkfb3 was most consistently upregulated, i.e. by 
DMOG (~8.5 fold), FG2216 (~7 fold), FG4592 (~9 fold), GSK1278863 (~6 fold) and Bay85-
3934 (~7.5 fold), while Pfkfb1 expression was not significantly changed. Significant Ldha 
upregulation was observed with FG2216 (~5 fold), GSK1278863 (~5 fold) and Bay85-3934 
(~2 fold). Bnip3 was significantly upregulated by FG4592 and Bay85-3934 with fold changes 
of ∼8 and ∼9, respectively. Phd2 was mildly upregulated by the PHD inhibitors, but 
significant fold change was seen by FG4592 (~5 fold). Vegf expression was upregulated in 
PC12 cells following 100 µM of FG4592 (~28 fold) and Bay85-3934 (~21 fold). Hif1α 
expression was not significantly changed by the PHD inhibitors. 
 
2.1.5. Effects of preconditioning with PHD inhibitors and re-oxygenation prior to OGD 
in PC12 cells  
We then studied whether pre-treatment with the PHD inhibitors followed by re-oxygenation 
was protective for PC12 cells against subsequent OGD insult. The effects of various 
concentrations (1, 10, 50 and 100 µM) were studied. PC12 cells were subjected to 24 hours 
PHD inhibitors treatment followed by a period of 24 hours reoxygenation prior to an OGD 
insult (6 hours, 0.3% O2). Six hours OGD (0.3% O2) led to about ~40 % of cell death, of 
which ~90 % were early apoptotic, ~10 % were late apoptotic/necrotic, and caused significant 
increase of LDH release (24.3%±2.3% vs 6.4%±2.2%) and reduction in MTT activity 
(73.6%± 12.3% vs 100%), compared to the normoxia control.  
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Pre-treatment with the PHD inhibitors at 100 µM for 24 hours followed by 24 hours of 
reoxygenation significantly reduced the cell death and LDH release caused by the 6 hours 
OGD (0.3% O2) compared to the vehicle (1% DMSO) pre-treated cells (Fig 6). These 
compounds at 100 µM, as well as FG4592 and Bay85-3934 at 50 µM significantly increased 
the MTT activities in cells after the OGD (Fig 6). FACS analysis (Fig. 7) of cells double 
stained with Annexin-V and 7-AAD revealed no significant difference in late 
apoptotic/necrotic (AV+/7-AAD+) cells between 1% DMSO (vehicle) and PHD inhibitors 
pre-treated groups. There was a significant reduction in early apoptotic cells when pre-treated 
with DMOG (15.7±4.9%), FG2216 (11.8±5.1%), FG4592 (16.9±7.1%), GSK1278863 
(10.7±4.8%) and Bay85-3934 (12.3±3.8%), in comparison to the 1% DMSO-treated cells 
(32.5±4.5%). The pretreatment of PHD inhibitors increased significantly in cell viable (AV-
/7-AAD-) to ~75-80% following the 6 hours OGD, compared to those pretreated by 1% 
DMSO (~55%).  
 
2.2. Primary rat neurons 
 
2.2.1. Effects of PHD inhibitors on primary rat cortical neurons viabilities in normoxia 
 
Similar to PC 12 cells, 1% DMSO did not cause significant changes in MTT activity and 
LDH release in primary neuron cultures (Fig. S3), and was used as the vehicle to dissolve 
FG4592 (10, 30, 50, 100 µM) and DMOG (100, 250, 500 µM, 1 mM and 2 mM) for studying 
their effects in primary neuron cultures. Since the 4 “clinical” compounds (FG4592, 
GSK1278863, Bay 85-3934, FG2216) had similar effects on the PC 12 cells, we used 
FG4592 as the representative to compare with DMOG (a non-specific 2-OG analogue) in 
primary neurons. Under 100 µM, neither FG4592 nor DMOG altered MTT activity, LDH 
release (Fig 8 A,B) and cell morphology (Fig 9).  DMOG at concentrations of 500 µM, 1 mM 
and 2 mM, however, caused significant LDH release and reduced MTT activities (Fig 8 A,B) 
as well as morphology changes in the neurons, such as shorter and fewer neurites, reduced 
nuclei densities per microscopic field (Fig 9).   
 
 
2.2.2. Effects of PHD inhibitors on autophagy  
In the primary neurons, 24 hours treatment with FG4592 and DMOG resulted in a significant 
increase in Lc3b-II/Lc3b-I ratio [FG4592 (30, 50 and 100 µM) and DMOG (250 and 500 
µM)], significant downregulation of p62 [FG4592 (50, 100 µM) and DMOG (100, 250 and 
500 µM)] (Fig 10). FG4592 (10 µM) did not result in significant changes in LC3b and p62 
expression (Fig. 10).  
 
2.2.3. Effects of PHD inhibitors on HIF-1α protein expression  
Both FG4592 and DMOG stabilized HIF-1 at lower concentration following 24 hours 
incubation in primary rat neurons compared to PC 12 cells. In primary neurons, FG4592 (30, 
50, 100 µM), and DMOG (100, 250, 500 µM) resulted in significant HIF-1 stabilisation (Fig. 
11). 
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2.2.4. Effects of preconditioning with PHD inhibitors and re-oxygenation prior to OGD 
in primary rat neurons  
Pre-treatment with the FG4592 (50, 100 µM) and DMOG (100, 250µM) for 24 hours 
followed by 24 hours of reoxygenation significantly increased the MTT activities in cells 
after the OGD and reduces LDH release caused by the 6 hours OGD (0.3% O2) compared to 
the vehicle (1% DMSO) pre-treated cells (Fig 12A,B). FG4592 (50, 100 µM) and DMOG 
(100 and 250 µM) pre-treated cultures comprised of primary neurons (Tuj1+ cells) with 
longer and many neurites, compared to those pretreated with the vehicle (1% DMSO) (Fig. 
13).  
 
3. Discussion  
Stroke is the fourth main cause of mortality in the UK and the leading cause of adult 
disability, with cerebral ischaemia representing the most prevalent type of stroke (accounting 
for ~87% of cases) (20). Over the past 30 years, various neuroprotective strategies for 
ischaemic stroke have failed to succeed in clinical trials due to the complex nature of stroke. 
Most of these strategies were aimed at targeting single molecules in the ischaemic cascade 
(21). Recent focus has shifted towards targeting the brain’s own endogenous protective 
mechanism (22, 23). Our study investigated one such promising approach known as 
ischaemic tolerance (7, 10, 11). 
 
Our study focused on analysing the most recent clinically advanced small molecule PHD 
inhibitors at biologically safe concentrations. These PHD inhibitors are being pursued for 
treatment of anaemia (24). We discovered that the PHD inhibitors stabilised HIF-1α in 
normoxia, and upregulated a number of known HIF target genes expression in PC12 cells. 
The PHD inhibitors induced autophagy, but not apoptosis in normoxia. Importantly, these 
PHD inhibitors protected the PC12 cells from OGD insults when given as preconditioning 
agents. Our studies were conducted using a PC12 cell model of ischaemia tolerance (25), as 
PC12 cells have been extensively used in neurobiological studies as models of Alzheimer’s 
disease, Parkinson’s disease, Huntington’s disease and ischaemic stroke (25-27). Since the 4 
“clinical” PHD inhibitors had the similar effects on the PC12 cells, we then used FG4592 as a 
representative novel PHD inhibitor alongside with DMOG, a non-specific 2-OG analogue, in 
primary rat neurons, to validate the results obtained from the PC 12 cells. Both FG4592 and 
DMOG stabilized HIF-1α in the neurons at lower concentrations compared to PC12 cells; 
suggesting neurons are more sensitive to PHD inhibitors than PC12 cells. Similarly, both 
FG4592 and DMOG protected the neurons from OGD insults when given preconditioning. 
 
At baseline, none of these compounds at 1-100 μM led to cytotoxicity (as assayed by LDH 
assays), cell death (as assayed by trypan blue exclusion assay) or apoptosis (as assayed by 
Annexin V/7-AAD staining) in PC 12 cells.  MTT activities were unchanged by the 
compounds except with FG4592 (100 µM) and Bay 85-8934 (50 & 100 µM), which 
significantly decreased MTT activities. In primary neuron culture, no significant LDH release 
and MTT activity alteration was seen by FG4592 (100 µM) and DMOG (100 µM). On the 
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other hand, DMOG (500 µM and above) resulted in significant LDH release and MTT 
activity reduction following 24 hours incubation in both PC 12 cells and primary neurons. 
MTT assay assesses mitochondrial catabolism and cell metabolic activity, which can be 
reduced in cells whilst retaining cell membrane integrity represented by LDH assay (28).  
 
Next, the role of the PHD inhibitors on three major autophagic marker, LC3, p62 and Beclin1 
was studied using rapamycin as a positive control inducer of autophagy (29). Beclin1 plays 
an important role in induction of autophagy. Upon induction of autophagy, cytosolic LC3-I is 
conjugated to phosphatidylethanolamine to form LC3-II, which is incorporated into the 
autophagosomal membrane. The p62 protein (sequestosome 1) binds to polyubiquitinated 
proteins through an ubiquitin-associated domain and combines with LC3-II through its LC3-
interaction region domain for attachment to the autophagosome, which is finally degraded in 
autolysosome. In the process of autophagy, p62 is continuously degraded. Beclin1, LC3-II 
and p62 have been used to monitor autophagic activity in various studies (30). Our results 
showed that both the PHD inhibitors (100 µM) and rapamycin (1, 10 µM) significantly 
increased LC3b-II/LC3b-I expression ratio. GSK1278863 (100 µM) and Bayer 85-3934 (100 
µM) promoted LC3-II expression to a similar extent as rapamycin (10 µM). FG4592, 
FG2216 and DMOG induced LC3-II expression to a lesser extent, but still significant extent. 
A subsequent downregulation of p62 was seen in cells treated with rapamycin and the PHD 
inhibitors in comparison to the vehicle (1% DMSO) - treated cells indicating degradation by 
autolysosomes was initiated. Our results are consistent with a study by Duran et al. (31) 
reporting inhibition of PHDs by DMOG for 5 hours in U2OS cells was sufficient to induce 
autophagy. Similarly, DMOG induced IC3-II accumulation and P62 degradation in HeLa 
cells (32). In a rat model of CKD, DMOG treatment for 1 week significantly increased 
autophagy (33). Li et al., (34) reported that FG4592 induced autophagy in SH-SY5Y cells via 
LC3II/LC3I upregulation and p62 downregulation. The “clinical” PHD inhibitors 
significantly upregulated Beclin1 in the PC12 cells, which is line with the study by Lu et al. 
(35) showed that HIF-1/BNIP3/Beclin1 signalling pathway modulates autophagy and 
contributes to hypoxia preconditioning-induced protection against OGD/Reperfusion.  
Although rapamycin promoted autophagy (shown by LC3-II upregulation and p62 
downregulation), it did not upregulate the expression of Beclin1. This is in line with studies 
by Li et al. (36) and Grishchuk et al. (37), which found that rapamycin promoted autophagy 
via a Beclin1 independent mechanism. They showed that rapamycin inhibited mTOR 
resulting in activation of Atg1 kinase complex to regulate autophagy.  
 
Autophagy is a self-catabolic process of damaged or dysfunctional cellular components, 
which are recycled for providing energy and nutrients (29). A number of studies 
demonstrate that mild/moderate autophagy has a neuroprotective effect on ischaemic stroke 
whereas insufficient or excessive autophagy results in nerve damage and cell death (22, 29). 
A study by Park et al. (38) showed ischaemic preconditioning (IPC) increased generation of 
autophagosomes and lysosomal activity. Blocking autophagic activity by 3-methyladenine 
during IPC ameliorated the neuroprotective effects of IPC, indicating that autophagy 
participates in IPC-induced neuroprotection. Similarly, Sheng et al. (39) showed that 
autophagy activation during IPC plays an important role in developing tolerance against a 
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subsequent fatal ischaemic insult. Yan et al. (40) showed that elevated autophagic activity 
contributed to increased tolerance against transient focal cerebral ischaemia in hyperbaric 
oxygen preconditioning while inhibition of autophagy using 3-methyladenine supressed the 
protective effective. Additionally, pre- and post- conditioning with rapamycin were found 
neuroprotective in various in-vivo and in-vitro studies (22, 41). 
 
At 100 μM, all the inhibitors except DMOG were able to accumulate HIF-1α significantly in 
the PC12 cells after 24 hours incubation at normoxia. We subsequently demonstrated, despite 
resulting in significant cytotoxicity DMOG at both 1 and 2 mM stabilized the HIF-1α in 
PC12 cells. This indicates that the 4 ‘clinical’ compounds have higher potency compared to 
DMOG for inducing HIF-1α in PC12 cells.  This conclusion is consistent with studies by 
Zhdanov et al. (42) in PC12 cells and by Chan et al., (19) in MCF-7 cells, where 1mM 
DMOG significantly stabilised HIF-1α. In the primary neurons, the HIF-1α was stabilised by 
FG4592 (30 μM)  and DMOG (100 μM), whose concentrations were significantly lower 
compared to those used in PC 12 cells. FG4592 clinical trial concentration is 30 µM (43). 50 
µM of FG4592 was shown to upregulate HIF-1α expression in SH-SY5Y cells in normoxia 
(31). In line with our results in primary rat neurons, Ogle et al., (9) treated primary rat 
neurons with DMOG (up to 500 µM) for 24 hours at normoxia and showed increased levels 
of HIF-1α protein. Badawi and Shi (44) treated primary rat neurons with 0.5, 1 and 2 mM 
DMOG and HIF-1α protein levels were significantly increased by 57%, 83% and 93% 
respectively. DMOG at 2 mM is close to it maximal effect as a higher concentration of 
DMOG did not cause further increase in the HIF-1α protein level.   
 
Six hours OGD (0.3% O2), led to about 40 % of cell death. Pre-treatment with the PHD 
inhibitors at 100 µM for 24 hours with 24 hours reoxygenation provided significant 
cytoprotection of both PC12 cells and primary neurons following 6 hours OGD. This is 
consistent with the study by Ogle et al. (9) that preconditioning with DMOG (100 μM) for 24 
hours prior to OGD significantly reduced OGD-induced neuron cytotoxicity. Jones et al. (45) 
reported that pre-treatment with DMOG > 30 µM for 20 hours prior to OGD significantly 
reduced OGD-induced neuronal death in a dose-dependent manner. DMOG induced 
protection has also been demonstrated in-vivo, in which the systemic application of DMOG 
before onset of cerebral ischaemia and throughout led to increased acute cerebral tissue 
preservation (7). Whilst, post-treatment with DMOG or FG4497 attenuated sensorimotor 
dysfunction in mice 3 days or 7 days after ischaemia-reperfusion injury (9, 11,18).  
 
There are few studies on the 4 ‘clinical’ PHD inhibitors in stroke research. GSK1278863 
(Daprodustat), a pyrimidinetrione-glycinamide, is at least partially, selective for the PHDs 
over other 2-OG dependent enzymes, which minimises off-target effects whilst also 
signifying an advantage over DMOG (5, 46). Another PHD inhibitor from GlaxoSmithKline, 
GSK360A has been shown to decrease the infarct volume and improve behaviour after 
transient MCAO in rats (12). FG2216 (IOX3) is structurally related to FG4592, and was 
replaced in clinical development by FG4592 following the appearance of adverse effects in 
clinical trial phase II (24). There is an additional phenoxy-group on the phenyl isoquinolyl 
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ring in FG4592, resulting in more efficient binding than FG2216 (5). FG2216 offered 
neuroprotective when pre-treating mice followed MCAO (10).  
Our study reveals that 6 hours OGD mainly results in apoptosis, rather than necrosis in the 
PC 12 cells, consistent with the previous studies (47). Pre-treatment with PHD inhibitors 
protected PC12 cells from apoptosis following OGD. These findings correlate with a finding 
of a study by Li et al. (34), where FG4592 reduced MPP+ (1-methyl-4-phenylpyridinium) 
induced apoptosis and improved mitochondrial function in SH-SY5Y cells. Apoptosis is 
energy-dependent, reversible programmed cell death that results in rapid clearance of cells by 
phagocytosis. HIF-1α stabilisation induces apoptosis by stabilising of tumour suppressor 
gene p53, which induces Bax and Bak proteins regulating the release of cytochrome C (48). 
HIF-1α stabilisation also results in upregulation of proapoptotic family members such as 
BNIP3, Noxa, Nix and downregulation of Bcl-2 (49). By contrast, HIF-1α can also protect 
cells from apoptosis by elevating Bcl-2 and Mcl-1 levels, Bcl-xL induction, and decreasing 
pro-apoptotic Bid, Bax, and Bak levels (50). In our study, the PHD inhibitors (100 µM) 
treatment for 24 hours stabilised HIF-1α, and protected the cells from a subsequent OGD 
injury.  
 
Hif1a gene expression was not significantly altered by the PHD inhibitors in the PC 12 cells 
despite the HIF-1α protein levels being significantly increased by the PHD inhibitors. Our 
observations are consistent with various studies that indicate that HIF-1α levels are mainly 
regulated at the post-transcriptional level (51, 52). During ischaemia, cells switch from 
oxidative phosphorylation to anaerobic glycolysis. Significant upregulation of Pfkfb3 was 
seen all the five PHD inhibitors, which is consistent with the study by Minchenko et al. (53) 
that revealed cobalt chloride, DFO and DMOG stimulated Pfkfb3 mRNA expression in 
Hep3b cells. PFKFB3 is ubiquitously expressed in several proliferating cells and tissues (54). 
No significant changes in Pfkfb1 in the PC12 cells by the PHD inhibitors were seen in this 
study. FG2216, GSK1278863 and Bay 85-3934 significantly upregulated the Ldha expression 
in PC12 cells, while FG4592 and DMOG did not. HIF signalling possesses feedback loops, 
e.g. PHD2 and PHD3 are upregulated in a negative feedback loop with HIF-1 stabilisation 
(55). The Phd2 expression was significantly upregulated by FG4592 in PC12 cells. FG4592 
and Bayer 85-3934 significantly upregulated Bnip3 and Vegf expression. It has been recently 
discovered that the upregulation of BNIP3 and BNIP3L provides a protective effect through 
promoting mitochondrial autophagy via competing with Bcl-2 releasing Beclin-1 (30). VEGF 
plays an important role in stimulating angiogenesis and neurogenesis resulting in increased 
blood flow and metabolism. VEGF also promotes cell survival by promoting survival-
promoting signalling pathways, such as serine-threonine protein kinase Akt signal 
transduction system and induction of anti-apoptotic pathways (56). VEGF is reported to 
reduce caspase-3 activation and cell death in an in-vitro model of cerebral ischaemia (57). 
Nevertheless, VEGF was shown to induce vascular permeability, resulting in oedema 
formation after stroke (56, 57).  
 
In conclusion, the HIF PHD inhibitors possess the capability to stabilise HIF-1α and to 
upregulate expression of a number of hypoxia genes that promote ischaemic tolerance. The 
PHD inhibitors induce autophagy in both PC 12 cells and primary neurons, but do not cause 
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apoptosis or cell death at 100 μM. DMOG is less potent in stabilising HIF-1α, autophagy 
induction and ischaemic tolerance compared to the ‘clinical’ PHD inhibitors. The 
pharmacological induced hypoxia adaptation requires coordination of intricate pathways and 
mechanisms, such as HIF, mTOR, autophagy. Further studies for precise understanding of the 
interplay of these mechanisms could lead to the development of new pharmacological 
strategies to minimize the damaging effects of strokes. 
 
 
4. Materials and methods  
  
4.1. Materials 
Rat adrenal pheochromocytoma (PC12) cells, Dulbecco’s Modified Eagle’s Medium 
(DMEM) containing high glucose (4.5 g/L), Dulbecco’s phosphate buffered saline (PBS), 
fetal bovine serum (FBS), inactivated horse serum (HS), poly-D-lysine (50x), trypsin (50x), 
Dimethyloxaloglycine (DMOG), rapamycin, 3-(4, 5-dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium bromide (MTT), dimethyl sulfoxide (DMSO), poly-D-lysine (50x), 
Trypan Blue, protease inhibitor cocktail, phenylmethylsulfonyl fluoride (PMSF), Tween-20, 
sodium chloride, Tris, glycine, sodium-dodecyl sulphate (SDS), dithiothreitol (DTT), Triton 
X-100, paraformaldehyde (PFA), bovine serum albumin (BSA), goat anti-rabbit IgG- FITC, 
goat anti-mouse IgG- FITC antibody were from Sigma-Aldrich (St Louis, MO,USA).  
Glucose-free Dulbecco’s modified eagle medium, Neurobasal medium, Glucose-free 
Neurobasal medium, penicillin and streptomycin (10000 units/mL & 10000 µg/mL), TrypLE 
(synthetic trypsin), Glutamax supplement, sodium pyruvate (100 mM), Hank’s Balanced Salt 
solution (HBSS), L-glutamine (200 mM), B27 supplement (50X, serum free), Pierce BCA 
protein assay kit and Pierce ECL western blotting substrates were from ThermoFisher 
Scientific (Loughborough, UK). Laemmli buffer (4x), 4-15% Mini-PROTEAN TGX Precast 
polyacrylamide gel, skimmed milk, Precision Plus Protein Dual Color Standard were from 
Bio-Rad (Hertfordshire, UK). Amersham™ Protran® Premium nitrocellulose blotting 
membranes were from VWR (Leicestershire, UK), RIPA (radio-immuno precipitation assay) 
buffer (10x) were from New England Biolabs Ltd (Hertfordshire, UK), Mouse anti- HIF-1α 
monoclonal antibody  was from Novus Biologics (Abington, UK), rabbit anti-p62 (SQSTM1) 
polyclonal antibody, rabbit anti-LC3B polyclonal antibody, and rabbit polyclonal anti-β-actin 
antibody were from Abcam (Cambridge, UK), rabbit polyclonal anti-Beclin1 polyclonal 
antibody from Cell signalling technology (Danvers, MA, USA), goat polyclonal anti-mouse 
IgG HRP affinity, anti-rabbit IgG HRP affinity were from Dako, Agilent (Santa Clara, CA, 
USA). Monoclonal mouse anti-Tuj1 was obtained from Biolegend (San Diego, CA, USA). 
Vectashield mounting medium with DAPI was obtained from Vector Laboratories 
(Burlingame, CA, USA).  
The Tetro cDNA synthesis kit and SensiFASTTM SYBR Hi-ROX kits were from Bioline 
Reagents Ltd (London, UK). The RNeasy plus Mini Kit was from Qiagen (Manchester, UK). 
The non-radioactive cytotoxicity assay kits were from Promega (Southampton, UK). The 
Guava cell dispersal reagent, Guava nexin kit, Guava instrument cleaning fluid, Guava 
Easycheck kit were from Merck Millipore (Burlingon, MA, USA). Plastic materials for cell 
cultures including pipettes, t25 cell culture vessel, 96-, 24- and 12-well plates, were from 
Greiner Bio-One (Gloucestershire, UK). 
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The PHD inhibitors, FG2216 (IOX3), FG4592, GSK1278863 and Bay 85-3934 were 
prepared, as reported (5). 
 
4.2. Cell culture  
 
4.2.1. PC12 cells 
PC12 cells were cultured in ‘complete’ medium (high-glucose DMEM (containing 4g/L 
glucose, L-glutamine and sodium bicarbonate, without pyruvate) supplemented with 5% 
FBS, 5% HS and 1% penicillin-streptomycin. PC 12 cells were incubated at 37 °C in a 
humidified atmosphere of 5% CO2 in air (ESCO cell culture CO2 incubator, Barnsley, UK). 
The plates and flasks used were coated with 5 mg/mL poly-D-lysine if required.  
 
4.2.2. Primary cortical rat neurons culture  
Rat embryos E17-18 were removed from a pregnant rat, which was humanely killed under 
Schedule 1 according to the Animals Scientific Procedures Act (1986) (ASPA). The work is 
exempt from the need for Animal Welfare and Ethical Review Board (AWERB) approval 
under the ASPA and all subsequent amendments under both UK and European Law. All 
animals used in this study have been treated in accordance with ASPA guidelines. The 
embryonic brains were placed in HBSS on ice and dissected, and the cortices removed into an 
Eppendorf containing cold Neurobasal medium. The Neurobasal medium was then removed 
and replaced with pre-heated (37oC) Neurobasal medium containing 0.05% trypsin and 100 
µg/mL DNAse and the cortices dissociated through pipetting. When dissociated, the cortices 
were placed in a 15 mL falcon tube and placed in the incubator (37oC) for 15 minutes. 
Thereafter, the cortices were removed and 6 mL pre-heated (37oC) Neurobasal medium 
containing 10% FBS added in order to inactivate the trypsin. The cortices were further 
dissociated through pipetting before the cell suspension was centrifuged in a Harrier 18/80R 
(MSE, East Sussex, UK) at 1500 rpm for 5 minutes. The supernatant was discarded, and the 
cells re-suspended in Neurobasal medium containing 2% B27 serum-free supplements, 2mM 
L-glutamine and 1% penicillin and streptomycin and filtered through a 70 micron filter. 
Neurons were then plated onto 5 mg/mL poly-D-lysine pre-coated plates at a density of 
approximately 0.15 x 106 cells per cm2. Thereafter, plates were placed in a standard incubator 
with a humidified atmosphere containing 5% CO2 at 37oC. Typically, experiments were 
performed at DIV 9-14. 
 
4.3. Procedure of oxygen and glucose deprivation (OGD)  
To mimic cerebral ischaemia in vitro, combined oxygen and glucose deprivation (OGD) was 
implemented. For OGD, the ‘complete’ medium was aspirated, and PC 12 cells rinsed twice 
with glucose-free media before incubation in glucose-free DMEM. PC 12 cells were then 
transferred into a purpose-built INVIVO2 400 humidified hypoxia workstation (Ruskinn 
Technologies, Bridgend, UK) with atmospheric conditions established at 0.3 % O2, 5% CO2, 
94% N2 and 37oC for 6 hours. For OGD in primary cortical neurons, neurons were switched 
to glucose-free Neurobasal medium containing 2% B27 serum-free supplements, 2mM L-
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glutamine and 1% penicillin and streptomycin. All other experimental parameters remained 
constant with PC12 cells.  
 
4.4. Drug administration  
The PHD inhibitors (DMOG, FG2216, FG4592, GSK1278863, Bay 85-3934) and an 
autophagy inducer (rapamycin) were initially dissolved in DMSO and subsequently diluted in 
the treatment appropriate culture medium to the indicated concentrations. To analyse the 
cytoprotective effects of the PHD inhibitors, final concentrations of 1, 10, 50 or 100 µM were 
applied in PC12 cells. The effect of rapamycin was studied at a final concentration of 1 and 
10 µM.  In primary rat cortical neurons, the PHD inhibitors DMOG and FG4592 were studied 
at varying concentrations as indicated. For the vehicle control group, a final concentration of 
1% (v/v) aqueous DMSO was used throughout. To study the cytotoxicity of PHD inhibitors 
initial experiments involved exposure for 24 h to varying concentration during normoxia in 
‘complete’ medium.  
The cytoprotective effects of the PHD inhibitors were tested in an ischaemic tolerance model 
(25). The cells were pre-treated with the PHD inhibitors for 24 hours, were then subjected to 
a period of reoxygenation (24 hours) by rapidly replacing the medium with normal 
‘complete’ media and returning cells to normoxia, thereafter the cells were treated with an 
OGD (0.3% O2) insult for 6 hours. 
 
4.5. Assessment of cell viability  
 
4.5.1. MTT Assays  
 
Cell viability was evaluated using the standard colorimetric assay for mitochondrial reductase 
catalysed reduction of yellow MTT to give a purple formazan product. PC12 cells were 
seeded on poly-D-lysine pre-coated 96-well plates at a density of 1.2 x 104 cells/well and 
cultured in ‘complete’ medium. Four hours prior to the completion of the experimental 
treatment, 10 μL of 5 mg/mL MTT solution diluted in PBS was added to the culture medium 
(final concentration, 0.5 mg/mL), and all samples incubated at 37°C under treatment 
conditions. On completion of treatment, the supernatant was aspirated and the formazan 
crystals formed by surviving cells were solubilised in 50 μL DMSO, then incubated at 37°C 
for 10 minutes. The optical density (OD) value of each well was determined by reading the 
absorbance at 540 nm using a microplate reader (Tecan Infinite M200 PRO, Switzerland). 
The DMSO background was subtracted from absorbance readings and the viability of cells 
for each treatment group was calculated based on equation 1; 
 
ܯܶܶ	(%	݋݂	ܿ݋݊ݐݎ݋݈) = ை஽	௩௔௟௨௘	(ா௫௣௘௥௜௠௘௡௧௔௟	௚௥௢௨௣ை஽	௩௔௟௨௘	(௖௢௡௧௥௢௟	௚௥௢௨௣) ݔ100%   (1) 
 
The viability of control cells (complete media in normoxic conditions) were assigned as 
100% viable, while treatment samples were normalised against the control group OD value. 
Results are expressed as the percentage of cells possessing the ability to reduce MTT. 
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4.5.2. Lactate dehydrogenase (LDH) release Assay  
 
Cell-membrane integrity was analysed by measuring LDH activity of the culture medium 
using a non-radioactive cytotoxicity assay kit. PC12 cells were seeded on poly-D-lysine pre-
coated 96-well plates at a density of 1.2 x 104 cells/well and cultured in ‘complete’ medium. 
Maximum LDH release control was generated by adding 10 µL 10x lysis solution to wells 
containing control cells, 45 minutes prior to adding the CytoTox reaction mixture. Following 
the completion of the experimental treatment, 50 µL of each sample medium was transferred 
to an unused 96-well flat bottom plate, into which, a further 50 µL of the reaction mixture 
containing tetrazolium salts was added. The subsequent mixture was incubated at room 
temperature for 30 minutes, protected from light. After 30 minutes, 50 µL of stop solution 
was added to each well and mixed. The amounts of formazan dye formed were assessed by 
measuring the absorbance with a microplate reader at 490 nm. The absorbance of the culture 
media background was subtracted from experimental values and the percent cytotoxicity 
calculated using Equation 2: 
ܲ݁ݎܿ݁݊ݐ	ܥݕݐ݋ݐ݋ݔ݅ܿ݅ݐݕ	(%) 	= 100 × ா௫௣௘௥௜௠௘௡௧௔௟	௅஽ு	ோ௘௟௘௔௦௘ெ௔௫௜௠௨௠	௅஽ு	ோ௘௟௘௔௦௘ 	   (2) 
The data are expressed as the mean percent of LDH release from the maximum control. 
 
4.5.3. Trypan blue exclusion assay  
 
Trypan blue exclusion was used to determine viable cells present in cell suspensions.  This 
assay is based on the principle that live cells possess intact cell membranes and exclude 
trypan blue dye. PC12 cells were seeded at density of 1.2x106 cells in T25 and incubated in 
the complete DMEM media. Following treatments, the cell suspension was transferred in 15 
ml sterile centrifuge tube and centrifuged for 5 minutes (100 relative centrifugal force (rcf)) 
using a Harrier 18/80R centrifuge (MSE, London, UK). The medium was aspirated and the 
cells were re-suspended in complete DMEM media. Cells clusters were mechanically broken 
by pipetting. 100 μL of the suspension was stained with 100 μL 0.4 % trypan blue for 5 
minutes. 10 μL of the trypan-blue treated cell suspension was applied to each side of the 
haemocytometer. Live cells possessing a clear cytoplasm and non-viable cells possessing a 
blue cytoplasm were counted in each culture. Five samples were analysed for each treatment 
condition. 
 
%	݈݅ݒ݁	݈݈ܿ݁ݏ = ௏௜௔௕௟௘	௖௘௟௟௦்௢௧௔௟	௡௨௠௕௘௥	௢௙	௖௘௟௟௦	(௏௜௔௕௟௘ାௗ௘௔ௗ) ݔ100%     (3) 
 
Cell viability was expressed as percentage of viable cells in the total number of cells based on 
the equation 3.  
 
4.6. Flow cytometry analysis  
 
A Guava Nexin Kit containing Annexin V and 7-AAD double stain was used to assess early 
apoptosis. Annexin V is a calcium-dependent phospholipid binding protein with affinity for 
phosphatidylserine (PS), a membrane component normally localized to the internal face of 
the cell membrane.  Early apoptosis results in translocation of PS molecules to outer surface 
of cell membrane where Annexin V can bind to them. 7-AAD is excluded in late- apoptotic 
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and dead cells. PC12 cells were plated at a density of 1 x 106 in T25 flasks and grown 
overnight at 37oC. At completion of identified treatment, 100 μl of cell suspension was 
transferred into 1.5 ml microcentrifuge tube. To break cells clusters, 50 μl 0.8x Guava cell 
dispersal reagent was added to the tube and incubated for 20 minutes at 37 °C. The cell 
suspension was microcentrifuged for 5 minutes (14,500g) and the culture medium was 
aspirated. 100 μl of DMEM and 100 μl of the Guava Nexin reagent were then added. The 
sample was stained for 20 minutes at room temperature, and were analysed using a Guava 
easyCyte flow cytometer (Merck Millipore, MA, USA).  Data were analysed using Guava 
analysis software (Merck Millipore, MA, USA). A total of 10000 events in the gate were 
acquired for each sample and three samples were acquired per condition. The data were 
expressed as percentage of cells in each quadrant. Cells in lower left quadrant represented 
viable cells (Annexin V and 7-AAD negative cells); the cells in lower right quadrant 
represent early apoptotic cells (Annexin V positive); cells in upper right column represent 
necrotic/late apoptotic cells (Annexin V and 7-AAD positive cells).  
 
 
4.7. Immunofluorescence 
Cell were fixed with 4 % paraformaldehyde (PFA) for 15 minutes, and then were 
permeabilised using 0.1% Triton X-100 in PBS for 15 minutes and blocked by incubating 
with 5% bovine serum albumin (BSA) in PBS-T (PBS+0.1% Triton X-100) for 1 hour in 
room temperature. This was followed by overnight incubation at 4°C with primary antibody 
(mouse anti-Tuj1, 1:1000 in 1% BSA in PBS-T). Following three PBS washes, cells were 
incubated in secondary antibody (goat anti-mouse IgG-FITC, 1:200 in 1% BSA in PBS-T) for 
2 hours at room temperature. Coverslips were then washed with PBS and mounted onto slides 
with Vectashield mounting medium with nuclear stain DAPI (4′, 6-diamidino-2-
phenylindole). Images were taken by Nikon Eclipse 80i fluorescence microscope (Japan), 
Hamamatsu (C4742-95) digital camera and were double merged (consisting of FITC Tuj1+; 
DAPI stained nuclei) with NIS-Element BR 3.22.14 software (Nikon, Tokyo, Japan). 
 
4.8. Protein extraction and analysis 
 
Cells were plated at a density of 1 x 106 in T25 flasks. After experimental treatments, the 
cells were washed with ice-cold PBS. Protein extraction buffer was made using 5 ml 1xRIPA 
buffer, 1mM PMSF (50 μL) and a protease inhibitor cocktail (50 μL). Ice cold lysis buffer 
(0.5ml per 75 cm2) was added and mixed on orbital shaker for 15 minutes. Adherent cells 
were scraped using plastic cold scraper and transferred to an ice-cooled microcentrifuge tube. 
The sample was sonicated (3 cycles of 10 seconds pulse with 5 seconds interval) (MSE 
Soniprep 150 Plus, Wolflabs, UK), and centrifuged for 10 minutes. The resulting supernatant 
was transferred to a new microcentrifuge tube and the protein concentrations were 
determined using a BCA protein assay kit following the manufacturer’s instructions.   
 
Twenty to 40 µg protein was denatured for 5 minutes in Laemmelli buffer at 95oC. Samples 
were loaded on to pre-cast 4-20% polyacrylamide miniPROTEAN TGX gels (10 wells). 10 
µl of Precision plus ProteinTM standards (10-250 kD) was loaded in each gel. The gels were 
run in 1x Tris/glycine/SDS running buffer in a BioRad Mini-PROTEAN® tetra cell at 100 
volts connected to a BioRad PowerPac Basic until the blue dye reached bottom (black line) of 
the gel. Following which the gels were removed from their cassettes into 1x transfer buffer. A 
trans-Blot SD Semi-Dry Electrophoretic transfer cell (Bio-Rad, Hertfordshire, UK) was used 
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for the transfer. Gels were placed onto a nitrocellulose membrane and assembled with extra-
thick filter paper. Transfer was performed at 12 volts for 1 hour. Membranes were blocked 
with 5% milk powder in 1x PBS-T for 1 hour then incubated overnight at 4°C with primary 
antibodies against anti- HIF-1α (1:500), anti-Lc3b (1:500), anti-Beclin1 (1:500), anti-p62 
(1:500) which were prepared in 1% milk powder in 1x PBS-T buffer. After the overnight 
incubation, membranes were washed in 1x PBS-T three times for 5 minutes each and were 
incubated for 1 hour in a horseradish peroxidise (HRP) conjugated secondary antibody, made 
in 1% milk powder in 1x PBS-T. After being washed three times with 1xPBS-T, the 
membranes were developed by Pierce ECL Western immunoblotting substrates, and imaged 
using FluorChem Western Blot imaging system (ProteinSimple, CA, USA) or ChemiDoc MP 
Imaging system (Biorad, UK). Thereafter, the membranes were stripped with mild-stripper 
buffer and re-probed with anti β-actin antibody (1:1000) and a subsequent HRP conjugated 
secondary antibody. The protein levels were quantified by densitometric analysis using Image 
J (NIH, USA). Values were normalized to β-actin and the corresponding controls. 
 
4.9. Quantitative Real-time Polymerase Chain Reaction (qRT-PCR)  
 
RNA was extracted from cells using the RNeasy plus Mini Kit. The cell pellet was harvested 
by transferring the cell suspension to 15 mL centrifuge tube and centrifuging (5 minutes, 100 
rcf). After which the supernatant was removed and 350 μL RLT plus containing 40 μM DTT 
was added to lyse the cell pellet. The homogenised lysate was then transferred to the supplied 
gDNA Eliminator spin column. The flow through was mixed with equal volume of 70% 
ethanol and transferred to an RNeasy spin column. The RNA pellets were washed with RW1 
and RPE buffer following the manufacturer’s instruction. The resultant RNA pellets were 
eluted in 50 μL nuclease-free water and the concentration measured on the NanoDrop 1000 
Spectrophotometer (ThermoFisher Scientific, Loughborough, UK). The quality of the RNA 
samples was assessed using the 260/280 and 260/230 absorbance measurements. After 
extraction, each sample was diluted to a total RNA concentration 2 μg and transferred to a 1.5 
mL RNase-free microcentrifuge tube on ice, ready for cDNA synthesis. Using Oligo(dT)18 
primers cDNA was synthesised using the Tetro cDNA synthesis kit in accordance with the 
manufacturer’s protocol. Amplification of 100 ng cDNA template per reaction was performed 
using a Techne PROPLATE48, using the SensiFAST SYBR Hi-ROX kit. Using a Techne 
Prime Pro 48 Real-time qPCR machine (ThermoFisher Scientific, Loughborough, UK), an 
initial activation step was performed for 2 minutes at 95oC before 40 cycles of a 3-step 
cycling program consisting of 95oC for 5 seconds, 60oC for 10 seconds and 72oC for 15 
seconds. The primers of a number of hypoxia genes [hypoxia-inducible factor 1α (Hif1α), 
BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 (Bnip3), HIF target gene prolyl 
hydroxylase 2 (Phd2), vascular endothelial growth factor (Vegf), 6-phosphofructo-2-
kinase/fructose-2,6-biphosphatase 1 (Pfkfb1), 6-phosphofructo-2-kinase/fructose-2,6-
biphosphatase 3 (Pfkfb3), lactate dehydrogenase A (Ldha)] used for analysis are in Table 1. 
Actin was used as a house keeping gene to normalise the relative levels of mRNA. β-Actin 
has been used as an internal loading control in PC12 cells for hypoxia treatment in previous 
studies (58, 59). Quantification of mRNA expression was performed using the comparative 
delta Ct method.  
 
4.10. Data analysis 
 
Experiments employing on the 96 well plate reader were performed with 3-8 well replicates. 
Independent experiments were performed in triplicate. The data is expressed as a mean value 
± standard deviation (S.D.). One-way ANOVA with Tukey multiple comparison post-hoc 
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was used to analyse comparisons among multiple groups. GraphPad PRISM 7 for Windows 
version 7.04 (GraphPad Software, Inc., CA, USA) was used for the analysis. Values of P < 
0.05 were considered statistically significant. 
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Table 1. List of primers used for qRT-PCR studies and their forward (FW)/reverse 
(RV) sequences. 
 
HIF1α 
 
FW TCAAGTCAGCAACGTGGAAG 
RV  TATCGAGGCTGTGTCGACTG 
Bnip3 
 
FW TTTAAACACCCGAAGCGCACAG  
RV GTTGTCAGACGCCTTCCAATGTAGA 
Phd2 
 
FW TGCATACGCCACAAGGTACG  
RV GTAGGTGACGCGGGTACTGC  
Vegf FW TTACTGCTGTACCTCCAC  
RV ACAGGACGGCTTGAAGATA 
Pfkfb1 FW AACCGCAACATGACCTTCCT 
RV CAACACAGAGGCCCAGCTTA 
Pfkfb3 FW CTGTCCAGCAGAGGCAAGAA 
RV CGCGGTCTGGATGGTACTTT 
Ldh-a FW AAGGTTATGGCTCCCTTGGC 
RV TAGTGACGTGTGACAGTGCC 
Actin FW TGCCCTAGACTTCGAGCAAGA 
RV CATGGATGCCACAGGATTCCATAC 
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FIGURE LEGENDS 
 
Figure 1. PC12 cells were cultured in normoxia (21% O2) for 24 hours with the PHD 
inhibitors (FG4592, FG2216, GSK1278863, Bay85-3934; concentration of 1, 10, 50, 100 
µM) and DMOG (1, 10, 50, 100, 250, 500 µM, 1 and 2 mM). (A). MTT assays (n=3) 
reveals reduction in mitochondrial activity (MTT release) in cells subjected to 100 µM of 
FG4592 and 50 & 100 µM of Bay85-3934 in comparison to 1% DMSO. The other inhibitors 
did not significantly affect mitochondrial activity. A significant reduction in MTT release 
was seen by 250, 500 µM, 1 and 2 mM of DMOG in comparison to 1% DMSO; (B). LDH 
assays (n=3) revealed no significant changes in structural integrity (% LDH release) with 
FG4592, FG2216, GSK1278863, Bay85-3934 at all concentrations. DMOG increased % 
LDH release and resulted in significant cytotoxicity at concentration of 500 µM, 1 and 2 mM;  
(C). Trypan blue exclusion assay (n=3) revealed no significant changes in % of live (trypan 
blue unstained cells) with FG4592, FG2216, GSK1278863, Bay85-3934 at all concentrations. 
DMOG significantly decreased % of live cells at concentration of 500 µM, 1 and 2 mM. Data 
were expressed as mean ± S.D.  * indicates P<0.05 against 1% DMSO treated PC12 cells 
(Two-way ANOVA, Tukey’s post-hoc analysis).  
 
Figure 2. Annexin-V and 7-AAD FACS analysis of PC12 cells treated with HIF-PHD 
inhibitors (100 µM) in normoxia (21% O2) for 24 hours. (A). Representative dot plots of 
Annexin-V/7-AAD FACS analysis of cells treated with the vehicle (1% DMSO) and the 
inhibitors. Cells in lower left quadrant represent viable cells, cells in lower right quadrant 
represent early apoptosis and cells in upper right quadrant represent late apoptosis/necrosis; 
(B) The group data (n=3) representing % of viable, early and late apoptotic cells. There was 
no significant different in any of the treatments groups compared to 1% DMSO treatment. 
Data were expressed as mean ± S.D.  
 
Figure 3. Immunoblot analysis of the protein expression of Lc3b-II, Lc3b-I, p62 and 
Beclin1 in PC12 cells treated with the indicated PHD inhibitors (100 µM) and 
rapamycin (1 & 10 µM) for 24 hours in normoxia. (A) Representative immunoblots of 
Lc3b-II, Lc3b-I, p62 and Beclin1 were shown alongside β-actin; (B) Normalised Lc3b-
II/Lc3b-I ratio measured after 24 hours exposure to the indicated PHD inhibitors and 
rapamycin in normoxia (n = 3). Significant increase in the Lc3b-II/Lc3b-I ratio was seen with 
rapamycin (1 & 10 µM) and 100 µM of DMOG, FG2216, FG4592, GSK1278863 and 
Bay85-3934. GSK1278863 and Bay85-3934 had a similar effect on the Lc3b-II/Lc3b-I ratio 
as Rapamycin; (C) Expression of p62 measured after 24 hours exposure to the indicated PHD 
inhibitors and rapamycin in normoxia (n = 3). Significant reduction in p62 expression in 
comparison to vehicle (1% DMSO)-treated cells was seen with rapamycin (1 & 10 µM) and 
100 µM of DMOG, FG2216, FG4592, GSK1278863 and Bay85-3934 treated cells; (D) 
Expression of Beclin1 measured after 24 hours exposure to the indicated PHD inhibitors and 
rapamycin in normoxia (n = 3). Significant upregulation of Beclin1 expression in comparison 
to vehicle (1% DMSO)-treated cells was seen in 100 µM of DMOG, FG2216, FG4592, 
GSK1278863 and Bay85-3934 treated cells, but was not in the Rapamycin treated cells. Data 
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were expressed as mean ± S.D. * indicated P<0.05 against 1% DMSO treatment (Two-way 
ANOVA, Tukey’s post-hoc analysis).  
 
Figure 4. Immunoblot analysis of HIF-1α levels in PC12 cells treated with 100 µM of the 
indicated PHD inhibitors and DMOG (100 µM, 500 µM, 1 mM, 2mM) for 24 hours in 
normoxia (21% O2). (A) Representative HIF-1α immunoblots were shown with those for β-
actin; (B) Graph (n=3) showed the normalised HIF-1α level measured at 24 hours after 
exposure to the indicated PHD inhibitors (100 µM) in normoxia. 24hours incubation with 100 
µM of FG2216, FG4592, GSK1278863 and Bay85-3934 significantly increased HIF-1α 
protein levels, while 100 µM DMOG did not change the HIF-1α proteinlevels; (C) Graph 
(n=3) showing normalised HIF-1α level at 24 hours after exposure to DMOG (100 µM, 500 
µM, 1 mM, 2mM) in normoxia. Both 1 mM and 2mM DMOG increased HIF-1α protein 
levels in normoxia. Data were expressed as mean ± S.D. * indicated P<0.05 against 1% 
DMSO treatment (Two-way ANOVA, Tukey’s post-hoc analysis).  
 
Figure 5. Effects of HIF PHD inhibitors on hypoxia gene expression. Expression of 
hypoxia genes, HIF1α, Bnip3, Phd2, Vegf, Pfkfb1, Pfkfb3, Ldha , after treatment with 100 
µM PHD inhibitors in normoxia for 24 hours were normalised to β-actin levels. Significant 
upregulation of Bnip3 and Vegf was seen with FG4592 and Bay85-3934. Phd2 was 
significant upregulated by FG4592. Pfkfb3 was significantly upregulated by DMOG, 
FG2216, FG492, GSK1278863, and Bay85-3934. Ldha was significantly upregulated by 
FG2216, GSK1278863 and Bay85-3934. HIF1α was not changed by any of the HIF PHD 
inhibitors. Each data point represented the mean and standard deviation of the relative fold 
change with respect to 1% DMSO-treated sample normalised to reference gene β-actin level. 
The dotted line represented basal gene expression. Statistical significance was indicated as 
*P< 0.05 (Two-way ANOVA, Tukey’s post-hoc analysis).  
 
Figure 6. The effect of preconditioning with HIF-PHD inhibitors followed by 24 hours 
re-oxygenation and 6 hours OGD on PC12 cells. PC12 cells were exposed to the PHD 
inhibitors (1, 10, 50 and 100 µM) for 24 hours in normoxia (21% O2) followed by 24 hours 
re-oxygenation (21% O2) and subsequent 6 hours OGD insult (0.3% O2). (A) MTT assay 
(n=3) showed greater mitochondrial activity after 6 hours OGD in cells preconditioned with 
100 µM of DMOG, FG2216, or GSK1278863 and 50 & 100 µM of FG4592 or Bay 85-3934 
compared to 1% DMSO pretreatment; (B) LDH assays (n=3) revealed reduced LDH release 
in cells preconditioned with 100 µM of DMOG, FG2216, FG4592, GSK1278863, or Bay 85-
3934 prior to 6 hours OGD compared to 1% DMSO pretreatment; (C) Trypan blue exclusion 
assays (n=3) reveal increased live (unstained) cells in cells preconditioned with 100 µM of 
DMOG, FG2216, FG4592, GSK1278863, or Bay 85-3934 prior to 6 hours OGD compared to 
1% DMSO pretreatment.  Data were expressed as mean ± S.D. * indicated P<0.05 against 1% 
DMSO (Two-way ANOVA, Tukey’s post-hoc analysis).  
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Figure 7. Annexin-V/7-AAD FACS analysis of PC12 cells preconditioned with the HIF 
PHD inhibitors followed by 24 hours re-oxygenation and 6 hours OGD. PC12 cells were 
exposed to PHD inhibitors (100 µM) for 24 hours in normoxia (21% O2), followed by 24 
hours re-oxygenation (21% O2) and subsequent 6 hours OGD treatment (0.3% O2). (A) 
Representative dot plots of Annexin-V/7-AAD FACS analysis of cells with the PHD inhibitor 
pre-treatment and 24 hours re-oxygenation followed by 6 hours OGD. Cells in the lower left 
quadrant represent viable cells, cells in the lower right quadrant represent early apoptosis and 
cells in upper right quadrant represent late apoptosis/necrosis; (B) The group data (n=3) 
representing % of viable, early and late apoptotic cells. Significant reductions in the fractions 
of early apoptotic cells were seen in cells preconditioned with 100 µM of DMOG, FG2216, 
FG4592, GSK1278863 and Bay 85-3934 in comparison to 1% DMSO-treated cells following 
24 hours re-oxygenation and 6 hours OGD. Data were expressed as mean ± S.D. * indicated 
significance of viable cells P<0.05 against 1% DMSO. # indicated significance of apoptotic 
cells P<0.05 against 1% DMSO (Two-way ANOVA, Tukey’s post-hoc analysis). 
 
Figure 8. Effect of HIF-PHD inhibitors on primary rat neurons during normoxia. 
Primary rat cortical neurons were cultured in normoxia (21% O2) for 24 hours with control (1 
% DMSO), FG4592 (concentration of 10, 30 50, 100 µM) and DMOG (100, 250, 500 µM, 1 
mM and 2 mM). (A). MTT assays (n=3) reveals no significant changes in mitochondrial 
activity in primary neurons subjected to 10- 100 µM of FG4592 (i), while a significant 
reduction in MTT activity was seen 500 µM, 1 mM and 2 mM of DMOG (ii), in comparison 
to control (1% DMSO) treated cells; (B). LDH assays (n=3) revealed no significant changes 
in LDH release (%) with FG4592 (10- 100 µM)(i), while a significant increase in % LDH 
release was seen by 500 µM, 1 mM and 2 mM of DMOG (ii) in comparison to control (1% 
DMSO) treated neurons.  
 
Figure 9. Representative double merged (FITC labelled neuron specific Tuj1 and DAPI 
stained nuclei) immunofluorescence images of primary rat neurons following FG4592 
and DMOG treatment in normoxia.  No morphological changes were observed with 
FG4592 treatment (10- 100 µM) and DMOG (100, 250 µM), but DMOG (500 µM, 1 mM 
and 2 mM) treatment resulted in neurons with shorter and fewer neurites and reduced cell 
densities per microscopic field.  
 
Figure 10. Effect of HIF-PHD inhibitors on the Lc3b-II/Lc3b-I and p62 expression in 
primary rat neurons. Immunoblot analysis of the Lc3b-II/Lc3b-I ratio and p62 in primary 
rat neurons treatment with 24 hours with control (1% DMSO), FG4592 (10, 30 50, 100 µM) 
and DMOG (100, 250 µM).  (A) Representative Lc3b-II/Lc3b-I and p62 immunoblots 
alongside β-actin; (B) Normalised Lc3b-II/Lc3b-I ratio measured after 24 hours exposure to 
FG4592 or DMOG in normoxia (n = 3). Significant increase in the Lc3b-II/Lc3b-I ratio was 
seen with FG4592 (50, 100 µM) and DMOG (250, 500 µM) in comparison to control (1% 
DMSO-treated cells); (C) Expression of p62 measured after 24 hours exposure to FG4592 or 
DMOG in normoxia (n = 3). Significant reduction in p62 expression in comparison to control 
(1% DMSO-treated cells) was seen 50, 100 µM of FG4592 and 100, 250, 500 µM of DMOG 
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treated cells. Error bars represent ±  S.D. * indicates P<0.05 against control (1% DMSO 
treatment) (Two-way ANOVA, Tukey’s post-hoc analysis).  
 
Figure 11. Effects of HIF-PHD inhibitors on HIF-1α levels in primary rat neurons. 
Immunoblot analysis of HIF-1α levels in primary cortical neurons treated with 24 hours with 
1% DMSO, FG4592 (10, 30 50, 100 µM) and DMOG (100, 250 µM) in normoxia. (A) 
Representative HIF-1α immunoblots were shown with those for β-actin; (B) Graph (n=3) 
showed the normalised HIF-1α level measured at 24 hours after exposure to FG4592 or 
DMOG in normoxia. FG4592 (30 µM onwards) and DMOG (100, 250 µM) significantly 
increased HIF-1α levels in primary rat neurons. Error bars represent ±  S.D. * indicates 
P<0.05 against control (1% DMSO treatment) (Two-way ANOVA, Tukey’s post-hoc 
analysis).  
 
Figure 12. The effect of preconditioning with HIF-PHD inhibitors followed by 24 hours 
re-oxygenation and 6 hours OGD on primary rat neurons. Primary cortical rat neurons 
were exposed to 1% DMSO, FG4592 (10, 30 50, 100 µM) and DMOG (100, 250 µM) for 24 
hours in normoxia (21% O2) followed by 24 hours re-oxygenation (21% O2) and subsequent 
6 hours OGD insult (0.3% O2). (A). MTT assay (n=3) showed greater mitochondrial activity 
after 6h OGD in neurons preconditioned with FG4592 (50, 100 µM) (i) and DMOG (100, 
250 µM) (ii) compared to 1% DMSO pretreatment;  (B).LDH assays (n=3) reveal reduced 
LDH release in cells preconditioned with FG4592 (50, 100 µM) (i) and DMOG (100, 250 
µM) (ii) prior to 6 h OGD compared to 1% DMSO pretreatment.  
 
Figure 13. Representative double merged (FITC labelled neuron specific Tuj1 and 
DAPI stained nuclei) immunofluorescence images of primary rat neurons 
preconditioning with FG4592 and DMOG followed by 6 hours OGD.  FG4592 (50, 100 
µM) and DMOG (100, 250 µM) preconditioned neurons displayed longer and more neurites 
than those pretreated with 1% DMSO.  
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